Relationship between plasma oxipurinol concentrations and xanthine oxidase activity in volunteers dosed with allopurinol
- PMID: 3190993
- PMCID: PMC1386565
- DOI: 10.1111/j.1365-2125.1988.tb03402.x
Relationship between plasma oxipurinol concentrations and xanthine oxidase activity in volunteers dosed with allopurinol
Abstract
1. 1-methyl xanthine (1-MX) is metabolized exclusively to 1-methyl uric acid (1-MU) by the enzyme xanthine oxidase. 2. The ratio of 1-MU to 1-MX in the urine, following a dose of 50 mg of 1-MX infused intravenously over 20 min, was used to measure the inhibition of xanthine oxidase induced by different doses of allopurinol. 3. Normal volunteers (n = 8) were given allopurinol 50, 100, 300 and 600 mg daily for 1 week each, in random order and 1 week separated each treatment. Inhibition of xanthine oxidase was assessed twice, on the last 2 days of each treatment week. 4. Steady-state oxipurinol concentrations increased linearly with increasing dose of allopurinol. 5. There was a hyperbolic relationship between the 1-MU/1-MX ratio and plasma oxipurinol concentrations, with an initial steep decline in the ratio which plateaued when plasma oxipurinol was around 4-6 mg l-1. This reduction in the ratio was quickly reversible upon cessation of allopurinol. 6. The 50% and 90% effective inhibitory oxipurinol concentrations, in relation to the 1-MU-/1-MX ratio were 1.4 +/- 0.46 and 4.08 +/- 2.03 mg l-1 respectively. 7. The concentration of oxipurinol required for almost complete inhibition of the enzyme was substantially less than those often observed in clinical practice.
Similar articles
-
Plasma oxipurinol concentrations during allopurinol therapy.Br J Rheumatol. 1987 Dec;26(6):445-9. doi: 10.1093/rheumatology/26.6.445. Br J Rheumatol. 1987. PMID: 3690140
-
Pharmacokinetics and pharmacodynamics of allopurinol in elderly and young subjects.Br J Clin Pharmacol. 1999 Oct;48(4):501-9. doi: 10.1046/j.1365-2125.1999.00041.x. Br J Clin Pharmacol. 1999. PMID: 10583019 Free PMC article.
-
Pharmacodynamics of oxypurinol after administration of allopurinol to healthy subjects.Br J Clin Pharmacol. 1996 Apr;41(4):299-304. doi: 10.1046/j.1365-2125.1996.03116.x. Br J Clin Pharmacol. 1996. PMID: 8730975 Free PMC article. Clinical Trial.
-
Allopurinol dosage selection: relationships between dose and plasma oxipurinol and urate concentrations and urinary urate excretion.Br J Clin Pharmacol. 1988 Oct;26(4):423-8. doi: 10.1111/j.1365-2125.1988.tb03401.x. Br J Clin Pharmacol. 1988. PMID: 3190992 Free PMC article.
-
Oxipurinol: alloxanthine, Oxyprim, oxypurinol.Drugs R D. 2004;5(3):171-5. doi: 10.2165/00126839-200405030-00008. Drugs R D. 2004. PMID: 15139781 Review.
Cited by
-
Disposition and uric acid lowering effect of oxipurinol: comparison of different oxipurinol formulations and allopurinol in healthy individuals.Eur J Clin Pharmacol. 1995;49(3):215-20. doi: 10.1007/BF00192382. Eur J Clin Pharmacol. 1995. PMID: 8665998 Clinical Trial.
-
Xanthine Oxidoreductase in Drug Metabolism: Beyond a Role as a Detoxifying Enzyme.Curr Med Chem. 2016;23(35):4027-4036. doi: 10.2174/0929867323666160725091915. Curr Med Chem. 2016. PMID: 27458036 Free PMC article. Review.
-
Interaction of allopurinol and hydrochlorothiazide during prolonged oral administration of both drugs in normal subjects. I. Uric acid kinetics.Clin Investig. 1994 Dec;72(12):1071-5. doi: 10.1007/BF00577758. Clin Investig. 1994. PMID: 7711418
-
Allopurinol reduces antigen-specific and polyclonal activation of human T cells.Front Immunol. 2012 Sep 21;3:295. doi: 10.3389/fimmu.2012.00295. eCollection 2012. Front Immunol. 2012. PMID: 23049532 Free PMC article.
-
Roles of selected non-P450 human oxidoreductase enzymes in protective and toxic effects of chemicals: review and compilation of reactions.Arch Toxicol. 2022 Aug;96(8):2145-2246. doi: 10.1007/s00204-022-03304-3. Epub 2022 Jun 1. Arch Toxicol. 2022. PMID: 35648190 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials